GlaxoSmithKline anticipates China will be its most important strategic market for the next 10 years. A senior GSK executive said GSK China achieved the third highest growth rate of all GSK companies, and it is estimated the Chinese medical market will be worth $14 billion by 2006 and $24 billion by 2010. GSK has already invested in five factory sites in the country and is moving more work there to maximize its resources.

Related Summaries